OncoNano Medicine and Gilead Sciences Partner to Evaluate ON-BOARD™ Delivery Tech for Oncology Drug Candidate

OncoNano Medicine announced a research collaboration with Gilead Sciences to test the company’s ON-BOARD™ nanotechnology encapsulation platform with one of Gilead’s oncology drug candidates, aiming to assess stability, selectivity, and efficacy of the encapsulated compound. Under the terms of the agreement, OncoNano will receive an upfront payment and could earn up to $300 million in milestone payments and royalties if Gilead expands the collaboration to additional targets.

Learn More